The company is developing investigational therapies including Tivoxavir marboxil (an endonuclease inhibitor for bird flu and seasonal influenza treatment) and TRX01/Ratutrelvir (an inhibitor for COVID-19). However, in June 2026, the planned Phase 2a human influenza challenge study of tivoxavir marboxil was deferred due to a negative review by the UK's Medicines and Healthcare Products Regulatory Agency (MHRA).
Cyborg Score Rationale
Net income turned positive in 2025, and key clinical studies are planned in the UK, while US trials face an FDA clinical hold pending toxicology data resolution. The company has cash runway extending to Q1 2027 as it advances backup influenza candidates. Recent regulatory setback in June 2026 creates near-term uncertainty.
Top Insights
Lead candidate tivoxavir marboxil's Phase 2a study deferred (June 2026) following MHRA negative review, though it demonstrated potent efficacy in animal models of highly pathogenic avian influenza.
US trials face FDA clinical hold pending toxicology data resolution, creating a bifurcated development strategy with UK studies continuing.
In February 2025, company regained compliance with NASDAQ minimum stockholders' equity requirement of $2.5 million after prior delisting risk.
Management has cash runway to Q1 2027 and is advancing backup influenza candidates with similar pharmacokinetic profiles to maintain pipeline momentum.
Named Competitors
CD388 — Antiviral candidate for respiratory viral diseases
Tamiflu — Established seasonal influenza antiviral treatment
Baloxavir — Cap-dependent endonuclease inhibitor for influenza
Recent Developments
(June 2026) Phase 2a study of tivoxavir marboxil deferred following negative MHRA review
(May 2026) Company filed to sell 35.9M shares of common stock
(April 2026) Q4 2025 earnings released; achieved net income positive year
(February 2025) Regained NASDAQ compliance after stockholders' equity shortfall
Open the full interactive Traws Pharma, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.